Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 6/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.57 |
| ▸ | FYN | P06241 | 11/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949469 | 0.90 | FGFR3 (0.59) | FGFR3FGFR1FYNKDR | |
| SCHEMBL9950181 | 0.87 | FGFR3 (0.68) | FGFR3KDR | |
| SCHEMBL9949831 | 0.80 | FGFR3 (0.55) | FGFR3FGFR1FYNKDR | |
| SCHEMBL9949521 | 0.80 | FGFR3 (0.52) | FGFR3FGFR1FYNKDRNTRK1 | |
| SCHEMBL10145480 | 0.78 | FYN (0.49) | FGFR3FGFR1FYNKDR | |
| SCHEMBL15981029 | 0.78 | CDK8 (0.52) | FGFR3FGFR1NTRK1PDGFRBKIT | |
| SCHEMBL9960949 | 0.77 | FGFR3 (0.46) | FGFR3FGFR1FYNKDR | |
| SCHEMBL9949714 | 0.77 | CDK8 (0.51) | FGFR3FGFR1FYNNTRK1PDGFRB | |
| SCHEMBL9950098 | 0.76 | FGFR3 (0.70) | FGFR3KDR | |
| SCHEMBL10181279 | 0.75 | FGFR3 (0.55) | FGFR3FGFR1FYNNTRK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2017-06-15 | — | — | US | disclosed |
| US-9533954-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-9533954-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2017-01-03 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754114-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | INCYTE CORPORATION (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION | 2012-06-28 | — | — | US | disclosed |
| WO-2012088266-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | INCYTE CORPORATION (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240220-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885FGFR1 4/4885FYN 53/4885 |
| US-20120165305-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885FGFR1 4/4885FYN 53/4885 |
| US-10813930-B2 | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885FGFR1 4/4885FYN 53/4885 |
| US-20170165263-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885FGFR1 4/4885FYN 53/4885 |
| US-20140243308-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 | FGFR3, FGFR4, FGFR2 | FGFR3 1/4885FGFR1 4/4885FYN 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.